Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LUPANETA PACK vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Leuprolide is a synthetic Gn RH analog that desensitizes pituitary Gn RH receptors, suppressing LH and FSH secretion, leading to decreased sex steroid production (testosterone in males, estrogen in females).
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Endometriosis,Uterine leiomyomata (fibroids),Central precocious puberty,Prostate cancer (palliative treatment),Breast cancer (off-label),Infertility (off-label as part of controlled ovarian hyperstimulation)
Prevention of pregnancy
Leuprolide acetate 3.75 mg intramuscularly every month or 11.25 mg intramuscularly every 3 months.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life is 6-12 hours (mean 8 hours). Clinical context: supports twice-daily dosing; prolonged in severe renal impairment (Cr Cl <30 m L/min).
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Leuprolide is primarily metabolized by peptidases and endopeptidases; norethindrone acetate is metabolized via reduction and conjugation (CYP3A4).
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal excretion accounts for approximately 50% of the total clearance as unchanged drug, with the remainder undergoing hepatic metabolism followed by biliary/fecal elimination (approx. 30% fecal, 20% biliary).
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
98% bound to albumin; saturable at high concentrations.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
0.2-0.3 L/kg (approx. 15-21 L in 70 kg adult), indicating limited extravascular distribution.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral bioavailability: 85-90% (first-pass metabolism minimal).
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment is required for renal impairment.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
No dose adjustment is required for hepatic impairment.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not approved for pediatric use.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
No specific dose adjustment is required; use with caution due to potential comorbidities.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
None for Lupaneta Pack specifically, but leuprolide components carry warnings for: (1) Initial tumor flare with transient increase in serum testosterone/estradiol leading to worsening of symptoms in prostate/breast cancer; (2) QT prolongation risk; (3) Hypersensitivity reactions including anaphylaxis.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Bone density loss with prolonged use; QT prolongation (avoid in patients with risk factors); tumor flare at initiation of therapy; anaphylaxis/hypersensitivity; depression; thromboembolic disorders; hepatic/renal impairment; pregnancy (Category X); lactation; hyperglycemia/diabetes; pituitary apoplexy (rare).
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Pregnancy (Category X), lactation, undiagnosed abnormal vaginal bleeding, known or suspected breast cancer (for norethindrone component), thromboembolic disorders, hepatic disease (for norethindrone component), hypersensitivity to Gn RH agonists or any component.
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No significant food interactions. Grapefruit juice may slightly increase estrogen levels; avoid large amounts. St. John's wort (herbal supplement) reduces contraceptive efficacy.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
LUPANETA PACK (levonorgestrel/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure: no increased risk of major birth defects beyond background rate; postfertilization effects not expected. Second/third trimester: androgenic effects on female fetus, including clitoral enlargement and labial fusion; possible cardiovascular and limb defects at high doses. Overall risk is low with unintentional early exposure.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Small amounts of ethinyl estradiol and levonorgestrel excreted in breast milk. M/P ratio for levonorgestrel ~0.37, ethinyl estradiol <0.01. May reduce milk production and quality; use only if benefits outweigh risks. Avoid during established lactation if alternative contraception available.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
No dose adjustment recommended because drug is contraindicated in pregnancy. Discontinue immediately if pregnancy occurs. Pharmacokinetic changes in pregnancy (increased clearance of sex hormones) are not applicable due to contraindication.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
LUPANETA PACK is a combined hormonal contraceptive containing estradiol valerate and dienogest. Monitor for thromboembolic events, especially in smokers over 35. Advise use of backup contraception during first 7 days of initiation. Consider CYP3A4 interactions with rifampin, anticonvulsants, and St. John's wort.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one tablet daily at the same time, in the order specified on the pack, starting on day 1 of menstruation.,Missed dose management: if late by less than 12 hours, take immediately and continue regular schedule; if more than 12 hours, consider backup contraception for 7 days.,Seek emergency care for signs of blood clots: sudden severe headache, chest pain, leg swelling, or vision changes.,Common side effects include nausea, breast tenderness, mood changes, and spotting.,Use additional non-hormonal contraception if taking antibiotics or other interacting medications.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LUPANETA PACK vs ALYACEN 1/35, answered by our medical review team.
LUPANETA PACK is a Oral Contraceptive that works by Leuprolide is a synthetic Gn RH analog that desensitizes pituitary Gn RH receptors, suppressing LH and FSH secretion, leading to decreased sex steroid production (testosterone in males, estrogen in females).. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LUPANETA PACK and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LUPANETA PACK is: Leuprolide acetate 3.75 mg intramuscularly every month or 11.25 mg intramuscularly every 3 months.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LUPANETA PACK and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LUPANETA PACK is classified as Category C. LUPANETA PACK (levonorgestrel/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure: no increased risk of major birth defects beyond background rate; postfer. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.